Dvant Pharma, Inc. filed a Form D with the Securities and Exchange Commission on 2026-10-13.
Dvant Pharma, Inc. filed a Form D notice of an exempt securities offering with the SEC on October 13, 2026. The filing reports $1.23M sold. Its industry group is Biotechnology. It names Andrew Kocab (Executive Officer, Director), Mukesh Nyati (Executive Officer, Director), Vincent Alessi (Director) (SEC Form D, October 13, 2026).
Sell to companies like Dvant Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-10-13 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Dvant Pharma, Inc.
Free to see. No signup.
More on the people and the money behind Dvant Pharma, Inc., from the filings we hold.
Biotechnology raises by companies based in Michigan, filed within 90 days of this one, largest first.
Get an email when Dvant Pharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Dvant Pharma, Inc. raises, hires or launches. No email unless you switch it on.
Watch Dvant Pharma, Inc. →Get the full cited report on Dvant Pharma, Inc.
What the filing shows about Dvant Pharma, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Dvant Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $1.23M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Andrew Kocab is named as Executive Officer and Director on the Form D that Dvant Pharma, Inc. filed with the SEC on 13 October 2026, one of 5 people that filing names.
Mukesh Nyati is named as Executive Officer and Director on the Form D that Dvant Pharma, Inc. filed with the SEC on 13 October 2026, one of 5 people that filing names.
Vincent Alessi is named as Director on the Form D that Dvant Pharma, Inc. filed with the SEC on 13 October 2026, one of 5 people that filing names.
Jim Adox is named as Director on the Form D that Dvant Pharma, Inc. filed with the SEC on 13 October 2026, one of 5 people that filing names.
Frank Perabo is named as Director on the Form D that Dvant Pharma, Inc. filed with the SEC on 13 October 2026, one of 5 people that filing names.
5 people named on the filing — 2 holding an executive role and 3 as directors only.
Named as of the 2026-10-13 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Dvant Pharma, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Dvant Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Dvant Pharma, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Dvant Pharma, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Dvant Pharma, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Dvant Pharma, Inc.. With no account yet, you sign up free and land on the result.
On these lists: The rest of the US raises, week of 2026-10-12 · Biotech raises, week of 2026-10-12
https://mentionfox.com/funding/dvant-pharma-inc-form-d-000001